Single User License
INR 136040
Site License
INR 272080
Corporate User License
INR 408120

Service Tax Additional

select a format
Price

Single User License
USD 2000
Site License
USD 4000
Corporate User License
USD 6000

Alternatively

Request a quote
Request a Customized research
Request for Sample Report





Recent Viewed Reports


Why Ken Reasearch?


Testimonials

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ... "Prashant Bhagwat,General Manager, Mahindra"

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!... "Jestin Mathew, Indonesian Trade Promotion Center"

The Report was very interesting and useful for me... "Marketing Manager, Western Union Business Solutions"

Ken Research completed the report successfully with tough deadline and large requirement. Really appreciate it... "Sales Manager, Largest India Aesthetic Laser Manufacturer"

We found the report really useful in understanding the complex Indian market and it provided lots of high quality insights. On the basis of this we commissioned Ken to produce a bespoke follow up to answer some specific questions about our market. This is now being used to help develop our marketing and sales strategy. We were very pleased with the comprehensive coverage, detail provided and actionable insights.... "Owner, Therefore Consulting UK"


Ischemia-Pipeline Review, H1 2015

Ischemia-Pipeline Review, H1 2015


  Request for Sample Report

Executive Summary

Ischemia-Pipeline Review, H1 2015

Summary

Global Markets Direct's, 'Ischemia-Pipeline Review, H1 2015', provides an overview of the Ischemia's therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Ischemia, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Ischemia and special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

The report provides a snapshot of the global therapeutic landscape of Ischemia

The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in the therapeutics development for Ischemia and enlists all their major and minor projects

The report summarizes all the dormant and discontinued pipeline projects

A review of the Ischemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources

Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages

A detailed assessment of monotherapy and combination therapy pipeline projects

Coverage of the Ischemia pipeline on the basis of target, MoA, route of administration and molecule type

Latest news and deals relating related to pipeline products

Reasons To Buy

Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Develop strategic initiatives by understanding the focus areas of leading companies

Identify and understand important and diverse types of therapeutics under development for Ischemia

Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline

Devise corrective measures for pipeline projects by understanding Ischemia pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 7

Introduction 8

Global Markets Direct Report Coverage 8

Ischemia Overview 9

Therapeutics Development 10

Pipeline Products for Ischemia-Overview 10

Pipeline Products for Ischemia-Comparative Analysis 11

Ischemia-Therapeutics under Development by Companies 12

Ischemia-Therapeutics under Investigation by Universities/Institutes 17

Ischemia-Pipeline Products Glance 19

Late Stage Products 19

Clinical Stage Products 20

Early Stage Products 21

Unknown Stage Products 22

Ischemia-Products under Development by Companies 23

Ischemia-Products under Investigation by Universities/Institutes 27

Ischemia-Companies Involved in Therapeutics Development 28

Alize Pharma SAS 28

Amyndas Pharmaceuticals LLC 29

AnGes MG, Inc. 30

Apceth GmbH & Co. KG 31

Athersys, Inc. 32

Bioheart, Inc. 33

Caladrius Biosciences, Inc. 34

Cellmid Limited 35

CoDa Therapeutics, Inc. 36

CohBar Inc. 37

DNAVEC Corporation 38

GlaxoSmithKline Plc 39

Hemostemix Ltd 40

IntelliCell BioSciences Inc. 41

Juventas Therapeutics, Inc. 42

Kasiak Research Pvt. Ltd. 43

Lixte Biotechnology Holdings, Inc. 44

Mast Therapeutics, Inc. 45

Mesoblast Limited 46

Miltenyi Biotec GmbH 47

Mirrx Therapeutics A/S 48

Multi Gene Vascular Systems Ltd 49

Nyken BV 50

Opsona Therapeutics Limited 51

Pathfinder Cell Therapy, Inc. 52

PharmaIN Corporation 53

Pharmicell Co., Ltd. 54

Pluristem Therapeutics Inc. 55

ReNeuron Group Plc 56

Sihuan Pharmaceutical Holdings Group Ltd. 57

Stempeutics Research Private Limited 58

Taxus Cardium Pharmaceuticals Group Inc. 59

TikoMed AB 60

Vericel Corporation 61

ViroMed Co., Ltd. 62

Ischemia-Therapeutics Assessment 63

Assessment by Monotherapy Products 63

Assessment by Target 64

Assessment by Mechanism of Action 66

Assessment by Route of Administration 68

Assessment by Molecule Type 70

Drug Profiles 72

AB-002-Drug Profile 72

ACP-01-Drug Profile 73

AdipoCell-Drug Profile 75

Alecmestencel-T-Drug Profile 77

alferminogene tadenovec-Drug Profile 78

AntimiR-199a-Drug Profile 80

ASCT-01-Drug Profile 81

Autologous Vascular Cells Therapy-Drug Profile 82

AZP-531-Drug Profile 83

beperminogene perplasmid-Drug Profile 84

bucillamine-Drug Profile 89

CD-52-Drug Profile 90

Cell Therapy for Critical Limb Ischemia-Drug Profile 91

Cell Therapy for Ischemia-Drug Profile 92

Cellgram for Severe Lower Limb Ischemia-Drug Profile 93

Cinepazide Mesylate-Drug Profile 94

CLBS-10-Drug Profile 95

CMK-103-Drug Profile 97

daprodustat-Drug Profile 98

DVC1-0101-Drug Profile 100

EP-80317-Drug Profile 101

Gene Therapy for Critical Limb Ischemia and Peripheral Arterial Disease-Drug Profile 102

Gene Therapy for Ischemic Heart Failure-Drug Profile 103

Gene Therapy to Activate Vascular Endothelial Growth Factor for Cardiovascular Disease and Central Nervous System Disorders-Drug Profile 104

hbEGF-Drug Profile 105

Humanin-Drug Profile 106

ixmyelocel-T-Drug Profile 108

JVS-100-Drug Profile 111

JVS-200-Drug Profile 113

LB-100-Drug Profile 114

LB-102-Drug Profile 116

MicroRNA for Ischemia-Drug Profile 117

MPC-25IC-Drug Profile 118

MultiGeneAngio-Drug Profile 119

MultiStem-Drug Profile 120

NRP-2945-Drug Profile 123

NYK-1112-Drug Profile 125

Oligonucleotide to Inhibit miRNA-26 for Ischemic Cardiovascular Disease-Drug Profile 126

Oligonucleotides for Immunology, Oncology, Infectious and Cardiovascular Disorders-Drug Profile 127

OPN-305-Drug Profile 128

Pathfinder Cells-Drug Profile 130

Peptagon-Drug Profile 132

PLX-PAD-Drug Profile 133

PMC-6-Drug Profile 137

Protein for Myocardial Infarction and Critical Limb Ischemia-Drug Profile 139

PT-00114-Drug Profile 140

Recombinant Peptide to Activate FPR2 for Ischemia Reperfusion Injury and Myocardial Ischaemia-Drug Profile 141

Recombinant Protein for Critical Limb Ischemia-Drug Profile 142

Recombinant Protein for Ischemia-Drug Profile 143

Recombinant Protein to Inhibit CXCL for Cardiovascular and Immunology-Drug Profile 144

Refacell-CLI-Drug Profile 145

ReN-009-Drug Profile 146

Small Molecule to Inhibit Arginase-1 and Arginase-2 for Myocardial Ischemia and Ischemia Reperfusion Injury-Drug Profile 147

Small Molecules for Ischemia and Reperfusion Injury-Drug Profile 148

Small Molecules for Renal Failure and Renal Ischemia-Drug Profile 149

Small Molecules to Activate Heat Shock Protein H11 Kinase for Myocardial Ischemia-Drug Profile 150

Small Molecules to Antagonize TRPM7 for Myocardial Ischemia and Glaucoma-Drug Profile 151

Small Molecules to Inhibit Mst1 for Myocardial Ischemia-Drug Profile 152

Stem Cell Therapy for Cardiovascular Disease-Drug Profile 153

Stem Cell Therapy for Cardiovascular Diseases-Drug Profile 155

Stem Cell Therapy for Critical Limb Ischemia-Drug Profile 157

Stem Cell Therapy for Critical Limb Ischemia-Drug Profile 158

Stem Cell Therapy to Activate VEGF for Critical Limb Ischemia-Drug Profile 159

Stempeucel-Drug Profile 160

Stromal Cell Therapy for Critical Limb Ischemia-Drug Profile 163

TM-700-Drug Profile 164

vepoloxamer-Drug Profile 165

VM-202-Drug Profile 167

Ischemia-Recent Pipeline Updates 169

Ischemia-Dormant Projects 212

Ischemia-Discontinued Products 218

Ischemia-Product Development Milestones 219

Featured News & Press Releases 219

Appendix 225

Methodology 225

Coverage 225

Secondary Research 225

Primary Research 225

Expert Panel Validation 225

Contact Us 225

Disclaimer 226

List of Tables

Number of Products under Development for Ischemia, H1 2015 15

Number of Products under Development for Ischemia-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 18

Number of Products under Development by Companies, H1 2015 (Contd..1) 19

Number of Products under Development by Companies, H1 2015 (Contd..2) 20

Number of Products under Development by Companies, H1 2015 (Contd..3) 21

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Development, H1 2015 26

Comparative Analysis by Unknown Stage Development, H1 2015 27

Products under Development by Companies, H1 2015 28

Products under Development by Companies, H1 2015 (Contd..1) 29

Products under Development by Companies, H1 2015 (Contd..2) 30

Products under Development by Companies, H1 2015 (Contd..3) 31

Products under Investigation by Universities/Institutes, H1 2015 32

Ischemia-Pipeline by Alize Pharma SAS, H1 2015 33

Ischemia-Pipeline by Amyndas Pharmaceuticals LLC, H1 2015 34

Ischemia-Pipeline by AnGes MG, Inc., H1 2015 35

Ischemia-Pipeline by Apceth GmbH & Co. KG, H1 2015 36

Ischemia-Pipeline by Athersys, Inc., H1 2015 37

Ischemia-Pipeline by Bioheart, Inc., H1 2015 38

Ischemia-Pipeline by Caladrius Biosciences, Inc. , H1 2015 39

Ischemia-Pipeline by Cellmid Limited, H1 2015 40

Ischemia-Pipeline by CoDa Therapeutics, Inc., H1 2015 41

Ischemia-Pipeline by CohBar Inc., H1 2015 42

Ischemia-Pipeline by DNAVEC Corporation, H1 2015 43

Ischemia-Pipeline by GlaxoSmithKline Plc, H1 2015 44

Ischemia-Pipeline by Hemostemix Ltd, H1 2015 45

Ischemia-Pipeline by IntelliCell BioSciences Inc., H1 2015 46

Ischemia-Pipeline by Juventas Therapeutics, Inc., H1 2015 47

Ischemia-Pipeline by Kasiak Research Pvt. Ltd., H1 2015 48

Ischemia-Pipeline by Lixte Biotechnology Holdings, Inc., H1 2015 49

Ischemia-Pipeline by Mast Therapeutics, Inc., H1 2015 50

Ischemia-Pipeline by Mesoblast Limited, H1 2015 51

Ischemia-Pipeline by Miltenyi Biotec GmbH, H1 2015 52

Ischemia-Pipeline by Mirrx Therapeutics A/S, H1 2015 53

Ischemia-Pipeline by Multi Gene Vascular Systems Ltd, H1 2015 54

Ischemia-Pipeline by Nyken BV, H1 2015 55

Ischemia-Pipeline by Opsona Therapeutics Limited, H1 2015 56

Ischemia-Pipeline by Pathfinder Cell Therapy, Inc., H1 2015 57

Ischemia-Pipeline by PharmaIN Corporation, H1 2015 58

Ischemia-Pipeline by Pharmicell Co., Ltd., H1 2015 59

Ischemia-Pipeline by Pluristem Therapeutics Inc., H1 2015 60

Ischemia-Pipeline by ReNeuron Group Plc, H1 2015 61

Ischemia-Pipeline by Sihuan Pharmaceutical Holdings Group Ltd., H1 2015 62

Ischemia-Pipeline by Stempeutics Research Private Limited, H1 2015 63

Ischemia-Pipeline by Taxus Cardium Pharmaceuticals Group Inc. , H1 2015 64

Ischemia-Pipeline by TikoMed AB, H1 2015 65

Ischemia-Pipeline by Vericel Corporation, H1 2015 66

Ischemia-Pipeline by ViroMed Co., Ltd., H1 2015 67

Assessment by Monotherapy Products, H1 2015 68

Number of Products by Stage and Target, H1 2015 70

Number of Products by Stage and Mechanism of Action, H1 2015 72

Number of Products by Stage and Route of Administration, H1 2015 74

Number of Products by Stage and Molecule Type, H1 2015 76

Ischemia Therapeutics-Recent Pipeline Updates, H1 2015 174

Ischemia-Dormant Projects, H1 2015 217

Ischemia-Dormant Projects (Contd..1), H1 2015 218

Ischemia-Dormant Projects (Contd..2), H1 2015 219

Ischemia-Dormant Projects (Contd..3), H1 2015 220

Ischemia-Dormant Projects (Contd..4), H1 2015 221

Ischemia-Dormant Projects (Contd..5), H1 2015 222

Ischemia-Discontinued Products, H1 2015 223

List of Figures

Number of Products under Development for Ischemia, H1 2015 15

Number of Products under Development for Ischemia-Comparative Analysis, H1 2015 16

Number of Products under Development by Companies, H1 2015 17

Number of Products under Investigation by Universities/Institutes, H1 2015 22

Comparative Analysis by Late Stage Development, H1 2015 24

Comparative Analysis by Clinical Stage Development, H1 2015 25

Comparative Analysis by Early Stage Products, H1 2015 26

Assessment by Monotherapy Products, H1 2015 68

Number of Products by Top 10 Targets, H1 2015 69

Number of Products by Stage and Top 10 Targets, H1 2015 69

Number of Products by Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2015 71

Number of Products by Top 10 Routes of Administration, H1 2015 73

Number of Products by Stage and Top 10 Routes of Administration, H1 2015 73

Number of Products by Top 10 Molecule Types, H1 2015 75

Number of Products by Stage and Top 10 Molecule Types, H1 2015 75

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Alize Pharma SAS

Amyndas Pharmaceuticals LLC

AnGes MG, Inc.

Apceth GmbH & Co. KG

Athersys, Inc.

Bioheart, Inc.

Caladrius Biosciences, Inc.

Cellmid Limited

CoDa Therapeutics, Inc.

CohBar Inc.

DNAVEC Corporation

GlaxoSmithKline Plc

Hemostemix Ltd

IntelliCell BioSciences Inc.

Juventas Therapeutics, Inc.

Kasiak Research Pvt. Ltd.

Lixte Biotechnology Holdings, Inc.

Mast Therapeutics, Inc.

Mesoblast Limited

Miltenyi Biotec GmbH

Mirrx Therapeutics A/S

Multi Gene Vascular Systems Ltd

Nyken BV

Opsona Therapeutics Limited

Pathfinder Cell Therapy, Inc.

PharmaIN Corporation

Pharmicell Co., Ltd.

Pluristem Therapeutics Inc.

ReNeuron Group Plc

Sihuan Pharmaceutical Holdings Group Ltd.

Stempeutics Research Private Limited

Taxus Cardium Pharmaceuticals Group Inc.

TikoMed AB

Vericel Corporation

ViroMed Co., Ltd.

Ischemia Therapeutic Products under Development, Key Players in Ischemia Therapeutics, Ischemia Pipeline Overview, Ischemia Pipeline, Ischemia Pipeline Assessment


Related Products in vertical
Other reports by publisher
Ken Research Pvt. Ltd. 27A, Tower B-2, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India
+91 1244230204

download

Company Brochure

Engage with Us

query [@] kenresearch.com